PROMISS Diagnostics

What PROMISS Diagnostics does

PROMISS Diagnostics, Inc. is a privately held, early-stage medical diagnostics company founded in 2017 and headquartered in Wauwatosa, Wisconsin. The company is developing a single core product, the PROMISS® test (Predicting Risk of Ovarian Malignancy In Serum Samples), a non-invasive, machine-learning-based blood diagnostic intended to enable early-stage detection of ovarian cancer. The proprietary algorithm ingests well-characterized, objective serum parameters and outputs a single score intended to distinguish benign from malignant adnexal (pelvic) masses, with company-stated performance claims of higher sensitivity and positive predictive value than the existing standard of care (CA125 biomarker and ultrasound).

The technology is designed to run on existing standard immunochemistry laboratory systems already deployed across most healthcare providers, eliminating the need for new assay development or instrumentation. PROMISS targets healthcare providers, payers, and patients across the ovarian cancer continuum, with explicit positioning across diagnostic aid, monitoring, and screening applications. The company is not yet at commercial launch: no pricing or named customers are disclosed, no revenue is reported, and the company's own website states it is "seeking clinical and investment partners." Total disclosed funding to date is approximately $400,000 in grant/early-stage capital from the Wisconsin Alumni Research Foundation (WARF), Northwestern Mutual, and Cream City Venture Capital.

Leadership comprises CEO Jalal Sulaiman (MBA, University of Chicago Booth; prior GE Healthcare operations leadership), Chief Medical Officer Dr. Roa Qato (board-certified Ob/Gyn with 14 years' clinical experience spearheading clinical research), and Chief Data Scientist Yolanda Hagar (PhD in Biostatistics with postdoctoral training in Applied Mathematics, biotech industry experience in multi-biomarker predictive modeling). WARF maintains a board seat, reflecting the technology's UW-Madison research origins and anchoring the governance structure around translational research and clinical validation milestones.

Name

PROMISS Diagnostics

Legal name

PROMISS Diagnostics, Inc.

Website

https://promissdx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

PROMISS Diagnostics is an early-stage Wisconsin-based diagnostics company developing the PROMISS® test, a machine-learning-driven, non-invasive blood assay designed to detect ovarian cancer at early stages on existing standard immunochemistry equipment.

Ownership category

akta.pro rank

Product category

Ovarian Cancer Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Ovarian cancer diagnostics
• Blood-based diagnostic test
• Machine learning diagnostics
• Cancer screening test
• Clinical diagnostic tools

Headquarters

HQ city

Wauwatosa

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Distribution channels1 record

Marketing channels1 record

Core offering

PROMISS Diagnostics develops the PROMISS test (Predicting Risk of Ovarian Malignancy In Serum Samples), a non-invasive, machine-learning based blood diagnostic test for the early detection of ovarian cancer. The test applies a proprietary algorithm to well-characterized, objective parameters from serum samples to generate a diagnostic score distinguishing benign from malignant pelvic masses, running on standard immunochemistry equipment already used by healthcare providers.

Product overview

PROMISS Diagnostics offers a single core diagnostic product: the PROMISS® test (Predicting Risk of Ovarian Malignancy In Serum Samples). This is a non-invasive, machine-learning based blood test designed for the early detection of ovarian cancer. The test uses a proprietary algorithm applied to blood sample parameters to generate a diagnostic score, distinguishing between benign and malignant masses in women with adnexal masses. The technology runs on existing standard immunochemistry systems already used by healthcare providers, positioning it as a low-cost, widely-accessible point-of-care diagnostic tool.

Differentiator

Problem solved

Functional benefit

Products and services

• PROMISS (Predicting Risk of Ovarian Malignancy In Serum Samples) A non-invasive, machine-learning based blood diagnostic test for the early detection of ovarian cancer, designed for clinicians and healthcare providers. The test uses a proprietary algorithm applied to well-characterized objective parameters from serum samples to generate a diagnostic score distinguishing benign from malignant pelvic masses in women with adnexal masses, and runs on existing standard immunochemistry equipment.

Quantifiable outcome

• Ovarian cancer survival rate increases from 17% at stage 4 diagnosis to 92% when detected at stage 1
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

One partnership is on record.

• B2C (BioClinical Consulting)minorStrategic or Co-development PartnerListed as a partner on the company website alongside WARF and Northwestern Mutual. Nature of partnership is not explicitly detailed.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Aspira Women's Health: Directly competes in ovarian cancer diagnostics with OVA1 and Overa, multivariate blood-based assays that assess malignancy risk in pelvic masses. Closely analogous in indication, clinical use case (distinguishing benign vs malignant adnexal masses), and patient population.
• Exact Sciences: Cancer screening diagnostics leader (Cologuard, Oncotype DX) using proprietary biomarker/algorithm approaches run on existing lab infrastructure. Comparable in business model (algorithm-anchored diagnostic with reagent kit), regulatory pathway, and target customer (healthcare providers and payers).

Broad incumbents

• Myriad Genetics: Established molecular diagnostics company with oncology focus, including hereditary cancer and tumor profiling tests. Comparable as a cancer IVD company selling algorithmic/molecular assays through healthcare providers with similar reimbursement and clinical-evidence dynamics.
• Roche Diagnostics: Largest IVD manufacturer and the incumbent provider of CA125, the current ovarian cancer biomarker standard of care. Comparable because it controls the existing clinical workflow PROMISS® aims to disrupt and operates the immunoassay platforms on which PROMISS® runs.
• Abbott Diagnostics: Major diagnostics manufacturer with broad IVD and immunoassay portfolios serving women's health and oncology. Comparable as an established immunoassay platform provider and competing assay developer in the ovarian cancer diagnostic workflow.

Emerging players

• GRAIL: Multi-cancer early detection company developing the Galleri blood-based screening test using methylation and machine-learning analysis. Comparable technology approach (ML on blood-based biomarkers for cancer detection) and end-goal (early-stage cancer screening).
• Guardant Health: Liquid biopsy leader (Guardant360, Shield) using blood-based cfDNA assays with advanced analytics for oncology. Comparable as a blood-based cancer diagnostics company leveraging proprietary algorithms to deliver actionable clinical information.
• Natera: Molecular diagnostics company with a growing oncology franchise (Signatera MRD test) that uses blood-based, algorithm-driven approaches. Comparable technology paradigm and commercial model targeting clinicians and payers.
• Freenome: Multiomics blood-based cancer screening company using machine learning on cfDNA and protein biomarkers. Highly comparable in technical approach (ML applied to serum/blood biomarkers for early cancer detection) and clinical mission (multi-cancer screening).
• VolitionRx: Blood-based cancer diagnostics company developing Nu.Q nucleosome-based assays for cancer detection. Comparable as a smaller, blood-based cancer diagnostics developer with multiple potential clinical applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PROMISS Diagnostics